Category: Clinical trials

Nabriva Initiates Second Phase 3 Clinical Trial of Lefamulin (“LEAP 2”) in Patients with Community-Acquired Bacterial Pneumonia (CABP)

VIENNA, Austria, and KING OF PRUSSIA, Pa., April 11, 2016 (GLOBE NEWSWIRE) -- Nabriva Therapeutics AG (NASDAQ:NBRV), a clinical stage biopharmaceutical company engaged in the research and development of novel anti-infective agents, with a focus on...

AstraZeneca and Eli Lilly and Company Announce Continuation of Pivotal Clinical Trial for People with Early Alzheimer’s Disease

8 April 2016 -- AstraZeneca and Eli Lilly and Company today announced that AMARANTH, a Phase II/III study of AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for early Alzheimer’s...

Sanofi and Regeneron Announce Positive Dupilumab Topline Results From Two Phase 3 Trials in Inadequately Controlled Moderate-To-Severe Atopic Dermatitis Patients

Paris, France and Tarrytown, NY - April 1, 2016 - Sanofi and Regeneron Pharmaceuticals, Inc. announced that two placebo-controlled Phase 3 studies evaluating investigational dupilumab in adult patients with inadequately controlled moderate-to-severe...

Phase 3 Study Findings Demonstrate Treatment With Baricitinib Results In Significant Improvements For Patients With Rheumatoid Arthritis Who Had Inadequate Response To Biologics

INDIANAPOLIS, March 31, 2016 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Incyte Corporation (NASDAQ: INCY) announced that detailed results of RA-BEACON — a pivotal phase 3 global study of baricitinib, a once-daily oral treatment...

MediciNova Announces Publication of Positive Findings from Completed Phase 1b Clinical Trial of MN-166 (ibudilast) in Methamphetamine Dependence

LA JOLLA, Calif., March 30, 2016 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that the...